MonaLisa Touch Cost in 2026: What 8 Clinics Actually Charge
Before you pay a $1,800–$3,000 treatment quote
A laser price is not a diagnosis or a complete treatment plan. Compare the symptom fit, exam needs, evidence, insurance reality, and five-year cash cost before you book.
Independent editorial research. Not medical advice, and not reviewed by a clinician. We are not affiliated with Cynosure, DEKA, or any clinic named on this page, and we earn nothing if you book MonaLisa Touch.
MonaLisa Touch cost runs $1,800 to $3,000 for an initial course in our eight-clinic U.S. price check; the median is $2,100. Using the six clinics that publish maintenance prices and four touch-ups over five years, the sample totals $3,800 to $5,100. Current payer policies we checked classify this use as investigational, not medically necessary, cosmetic, or non-covered.
This page is about MonaLisa Touch, the fractional carbon-dioxide (CO2) vaginal laser procedure marketed by Cynosure—not Leonardo da Vinci’s painting.
Best for: someone who has already had the right exam, understands that use for genitourinary syndrome of menopause is off-label, cannot or does not want to use other suitable treatments, and can absorb the full cash cost without needing a promised result.
Not for you if: you have unexplained postmenopausal bleeding, which needs evaluation before symptom treatment; or you have an undiagnosed lesion in the treatment area, an active vaginal or vulvar infection, pregnancy or fewer than three months postpartum, prolapse beyond the hymen, prior vaginal or colorectal radiation, prior reconstructive pelvic surgery with a mesh kit, impaired wound healing, a keloid history, anticoagulation treatment, or a thromboembolic condition. The latter conditions are on the manufacturer’s current contraindication list.
| The decision in one screen | Five-year price modeled from current public data | Regulatory or access reality |
|---|---|---|
| MonaLisa Touch — four paid touch-ups | $3,800–$5,100; sample median $4,550 | The laser platform is FDA-cleared for broad soft-tissue surgical uses; GSM is not named in the clearance |
| Generic estradiol vaginal cream — medication only | $462–$628 for 13–15 whole tubes in the label-based starting + maintenance model | FDA-approved prescription estrogen; pharmacy and insurance prices vary |
| Generic cream + one self-pay Midi intake and four yearly follow-ups | $1,312–$1,478 using 13–15 whole tubes | Virtual care; a separate in-person exam may still be needed |
| Intrarosa at the current displayed cash-discount price | About $15,200 | FDA-approved prescription steroid; the manufacturer says eligible commercially insured patients may pay as little as $35 per 28 inserts, with program terms to confirm |
| Osphena through the current direct program | About $1,825 with eligible commercial insurance or $3,853 without coverage | FDA-approved oral estrogen agonist/antagonist; program terms can change |
These figures compare cash outlay, not outcomes. Drug projections hold today’s price and program terms constant for five years; that is arithmetic, not a promise. The estradiol model includes the label’s low-to-high starting range, taper, and 1 g twice-weekly maintenance, but excludes visits, exams, labs, tax, shipping, and dispensing charges. The Intrarosa $35 manufacturer statement is not projected for five years because the public page does not establish a durable five-year term.
The first number is real. It just is not the whole number.
A clinic can quote $2,100 and still leave you with a five-year decision closer to $4,550 once the maintenance schedule is included. That is not a trick. It is what happens when the first three sessions are sold as the product and the recurring touch-up is treated like a footnote.
The comparison used to sell the laser can be just as incomplete. Mercy Health’s April 2026 page says vaginal estrogen can exceed $400 for a six-week tube. A brand-name cash price may reach that territory. The recurring transparent generic prices we recorded for a 42.5 g tube were $35.51 to $41.88. Using the label’s low-to-high starting range, taper, and then 1 g twice-weekly maintenance, five calendar years require about 13 to 15 whole tubes—roughly $462 to $628, not $400 every six weeks.
There is one version of the no-vaginal-estrogen lane where the math really can flip: Intrarosa bought every 28 days at the current displayed cash-discount price is far more expensive over five years than the laser sample. But that is not a blanket “laser is cheaper” conclusion. The current official Intrarosa patient site says eligible commercially insured patients may pay as little as $35 per 28 inserts, while Osphena’s current official direct-program arithmetic can land below the median laser model if eligibility and terms persist.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
What did The HRT Index verify for this page?
We did not average other cost articles. We opened eight U.S. clinic and health-system pages, recorded the package language, checked every published maintenance price, read current payer policies, pulled the FDA clearance record and current manufacturer safety information, and reran the alternative-cost math from current labels and prices. The resulting clinic numbers are provider-stated public data, not call-confirmed quotes.
For this update, we verified:
- Eight public clinic prices, from $1,800 to $3,000 for the initial course.
- Six public maintenance prices, from $500 to $750.
- Three insurer policies that directly name MonaLisa Touch or fractional vaginal laser, plus a current managed-care policy and the CMS national policy for laser procedures.
- The current Cynosure indication, contraindications, and listed side effects.
- FDA 510(k) K180193 for the DEKA SmartXide family, including SmartXide Touch.
- ACOG’s current statement that laser is neither FDA-approved nor FDA-cleared for menopause symptoms.
- The 2025 AUA/SUFU/AUGS GSM guideline, five highlighted sham-controlled trials, and the August 2026 comparator-aware meta-analysis.
- Current DailyMed labels for generic estradiol vaginal cream, Intrarosa, and Osphena.
- The current official Intrarosa and Osphena savings statements, plus current self-pay terms for Midi.
What no public-page audit can verify is the quote you will receive tomorrow, the exact contents of a local package, whether your individual insurance contract will make an exception, or how many maintenance sessions you personally would buy. Those belong in writing before payment.
How much does MonaLisa Touch cost in 2026?
In The HRT Index’s eight-clinic public price check, completed September 1, 2026, the initial course ranged from $1,800 to $3,000. The median was $2,100 and the arithmetic mean was $2,225. Six clinics published maintenance prices of $500 to $750, with a $600 median and a $608 mean.
| Clinic and market | Published initial course | Sessions included | Published maintenance | Stated interval | Price-page status |
|---|---|---|---|---|---|
| Duke Health — Durham, NC | $1,800 | 3–4 | $500 | Every 12–18 months | Page updated July 19, 2023; retrieved September 1, 2026 |
| Women’s Health Associates — Merriam/Leawood, KS | $1,800 | 3 | $600 | Every 12–18 months | No visible price effective date; retrieved September 1, 2026 |
| Horizons Health & Wellness — Bridgewater, MA | $1,800 maximum | 3 typical; page says no extra charge if more are needed | $600 | Every 12–18 months | No visible price effective date; retrieved September 1, 2026 |
| Mercy Health — Toledo, OH | $2,100 | 3 | Not published | Annual maintenance stated | Page published April 14, 2026 |
| Idaho Urologic Institute — Boise/Meridian/Nampa, ID | $2,100 | 3 | $750 | Not stated | No visible price effective date; retrieved September 1, 2026 |
| Rush University Medical Center — Chicago, IL | $2,500 | 3 | $600 | Annual | No visible price effective date; retrieved September 1, 2026 |
| Associates in Women’s Health Care — Roseville, CA | $2,700 prepaid | 3 internal + external sessions | $600 | Yearly | No visible price effective date; also lists $1,000 per combined single session; retrieved September 1, 2026 |
| Dr. Thaïs Aliabadi — Los Angeles, CA | $3,000 | 3 | Not published | Every 12–18 months stated | No visible price effective date; retrieved September 1, 2026 |
This is a public-price sample, not a national average. Clinics that publish are self-selecting. Six of the eight pages do not display a price effective date, so the table records what was visible on September 1, 2026; it does not pretend those clinics confirmed the number by phone.
Associates in Women’s Health Care also publishes a reduced breast-cancer-survivor price of $800 per combined treatment or $2,400 prepaid for three. We did not use that subgroup discount in the standard eight-clinic median.
What the sample does prove is that three-session packages for the same branded treatment are listed at $1,800 by Women’s Health Associates and Horizons and $3,000 by Dr. Aliabadi’s practice. That is a 67% spread before you reconcile scope, travel, consultation, external treatment, financing, or maintenance.
If your quote is above $3,000 for three sessions, you are above every initial-course price in this sample. That does not automatically make the quote wrong. It means the burden shifts to the clinic to show what is included that the public packages do not include.
You have the benchmark. Now separate “expensive” from “wrong treatment.”
Use Find My HRT Path to map the next step to your symptoms, history, insurance, and state.
What is actually included in a MonaLisa Touch quote?
A MonaLisa Touch quote usually covers a defined number of in-office laser sessions. Consultation, internal versus external treatment, numbing, follow-up, retreatment, maintenance, and refund terms vary by clinic. “Three treatments” does not mean the same package everywhere, so the written scope matters as much as the headline price.
Two clinics can both say “$2,100 for three treatments” and mean different things.
Ask for these eight items in writing:
- Exactly how many sessions are included? Duke publishes a three-to-four-session series. Horizons publishes $600 per treatment with a maximum initial charge of $1,800 and says it does not add a fee if more than three are needed. Those are not the same package.
- Is treatment internal only, external only, or both? Associates in Women’s Health Care publishes $500 for internal-only, $500 for external-only, and $1,000 when both are done in one session.
- Is the diagnostic consultation included? A separate visit may be billable under your medical benefits, but coverage depends on the visit, diagnosis, coding, network, and contract. Get the amount and billing plan before you go.
- Is topical anesthetic included? Do not assume “no anesthesia” means no comfort measures or no separate charge.
- Is a post-treatment check included? Ask whether a new symptom, possible infection, bleeding, or pain is handled within the package.
- What is the maintenance price? Mercy and Dr. Aliabadi state a maintenance interval but do not publish the maintenance price. That missing number can decide the five-year total.
- What happens if you stop after one or two sessions? Ask whether the package is refundable, transferable, or simply forfeited.
- What happens if there is no meaningful improvement? A retreatment policy is not the same thing as a guarantee. Ask whether another session would be offered and what it would cost.
There is no standard package definition across the eight pages. The cleanest quote is not the cheapest one. It is the one that makes every future dollar visible before the first dollar leaves your account.
How much does MonaLisa Touch cost over five years?
Six clinics publish both an initial-course price and a maintenance price. A three-touch-up model produces five-year totals of $3,300 to $4,500, with a $3,950 median. A four-touch-up model produces $3,800 to $5,100, with a $4,550 median. Both models are shown because a 12-to-18-month schedule does not produce one honest universal count.
| Clinic | Initial course | Three paid touch-ups | Five-year total: 3 touch-ups | Four paid touch-ups | Five-year total: 4 touch-ups |
|---|---|---|---|---|---|
| Duke Health | $1,800 | 3 × $500 | $3,300 | 4 × $500 | $3,800 |
| Women’s Health Associates | $1,800 | 3 × $600 | $3,600 | 4 × $600 | $4,200 |
| Horizons Health & Wellness | $1,800 | 3 × $600 | $3,600 | 4 × $600 | $4,200 |
| Idaho Urologic Institute | $2,100 | 3 × $750 | $4,350 | 4 × $750 | $5,100 |
| Rush University Medical Center | $2,500 | 3 × $600 | $4,300 | 4 × $600 | $4,900 |
| Associates in Women’s Health Care | $2,700 | 3 × $600 | $4,500 | 4 × $600 | $5,100 |
| Sample median | $3,950 | $4,550 | |||
| Sample mean | $3,942 | $4,550 |
This is arithmetic, not a prediction. The models assume you buy the published initial package and then three or four paid maintenance sessions. They exclude consultation, travel, time off work, external treatment not included in the package, taxes, card fees, and financing interest. They also do not predict how long any benefit would last for you.
Here is the number that belongs in the room before a credit card does: a $2,100 initial quote is only 46% of the $4,550 four-touch-up median model.
Financing changes the payment schedule, not the cost. Interest can make the total higher. A monthly payment that fits is still a five-year decision.
Does insurance cover MonaLisa Touch?
Expect self-pay. Every current written policy we found that directly addresses MonaLisa Touch or fractional vaginal laser treats the service as investigational, not medically necessary, cosmetic, or non-covered. That is strong evidence about the usual result, but it is not permission to speak for every plan: the contract, product, diagnosis, coding, and date of service still control.
| Payer and policy | Current policy language | Verification date |
|---|---|---|
| Aetna CPB 0427: Carbon Dioxide Laser | Says there is insufficient evidence to support MonaLisa Touch for gynecologic health, including vaginal atrophy and dyspareunia | Last review July 8, 2026 |
| Capital Blue Cross MP 4.047 | Fractional laser or fractional CO2 laser for vulvovaginal atrophy is investigational for all indications; rejuvenation or tightening for appearance or sexual performance is cosmetic | Effective March 1, 2026 |
| Arkansas Blue Cross and Blue Shield 2018019 | Names MonaLisa Touch and says the procedure does not meet primary coverage criteria or is not covered; for other contracts it is not medically necessary or investigational | Effective June 1, 2026; last review July 2026 |
| Healthy Blue North Carolina ANC.00009 | Vaginal rejuvenation or tightening is not medically necessary under all circumstances; coding section names laser for atrophy, including MonaLisa Touch | Last review May 14, 2026; published July 1, 2026 |
The wording changes from policy to policy. The money result usually does not.
“Investigational” is not a moral judgment about your doctor and it is not the same as “dangerous.” It means the plan does not accept the evidence as sufficient to establish improved health outcomes for that use. “Cosmetic” or “not medically necessary” may be a different exclusion under the contract. Ask which one is being applied, because the appeal route can differ.
Can you appeal? You can request a written benefit determination and use the appeal rights in your plan. But an appeal is harder when the policy excludes the procedure category itself rather than disputing whether you personally meet a covered criterion. Ask for the policy number, the exact denial reason, the procedure code, and the appeal deadline.
What about Medicare? CMS does have a national policy for laser procedures—NCD 140.5—but it does not affirmatively cover MonaLisa Touch for GSM. The NCD says that, when there is no specific national noncoverage instruction and the laser is marketed under FDA authority, a Medicare Administrative Contractor may decide whether the procedure is reasonable and necessary. That is local discretion, not a national yes.
A clinic’s “Medicare does not cover this” statement may still be the correct practical answer for that clinic, code, and contractor. It should not be inflated into a national rule that CMS itself has not written. Get the answer from the clinic and the plan in writing before treatment.
What about Medicaid? Medicaid coverage and managed-care policies vary by state and plan. The Healthy Blue North Carolina policy above is one current noncoverage example, not a fifty-state rule.
A separate diagnostic exam or consultation may be covered even when the laser is not. Ask whether the visit and the procedure are billed separately, which diagnosis and code will be used, whether the clinician is in network, and whether you will owe the visit charge if you decline the laser.
If a clinic says it may be covered, ask one sentence: “Which benefit, policy number, and procedure code do you expect my plan to pay?”
Can you use an HSA or FSA for MonaLisa Touch?
Possibly, but the clinic does not make the final tax or plan decision. IRS Publication 502 generally treats an expense as medical when its primary purpose is diagnosis, cure, mitigation, treatment, or prevention of disease, or affecting a body function; expenses primarily for appearance are excluded. Your HSA or FSA administrator can still require substantiation.
The word “medical” on a clinic page is not an eligibility ruling. Neither is the word “rejuvenation.”
Use this order:
- Ask the plan administrator before paying. Describe the procedure, the diagnosed condition, and the provider. Request the answer in writing.
- Ask what documentation it requires. That may include an itemized receipt, diagnosis, date of service, provider information, and a letter of medical necessity.
- Keep the records. An HSA distribution may be made later for a qualifying expense if the records support it, but an FSA follows the plan’s reimbursement and deadline rules.
- Do not assume a card swipe equals approval. A transaction can process and still be questioned during substantiation or audit.
The governing tax explanation is IRS Publication 502, not a laser clinic’s FAQ. This page is not tax advice.
Is MonaLisa Touch FDA approved?
No—not as a treatment for GSM, vaginal atrophy, vaginal dryness, painful sex, urinary symptoms, or other menopause symptoms. The underlying SmartXide Touch laser platform has FDA 510(k) clearance for broad soft-tissue surgical uses, including gynecology and genitourinary surgery. Those are different statements. Use for GSM is off-label.
This is the clean version:
- The device platform is FDA-cleared. FDA 510(k) K180193 covers the DEKA SmartXide family, including SmartXide Touch, as a powered CO2 surgical laser.
- The cleared indication is broad soft-tissue surgery. The FDA summary lists incision, excision, ablation, vaporization, and coagulation of soft tissue in specialties including gynecology and genitourinary surgery. It does not name GSM, vaginal atrophy, vaginal dryness, dyspareunia, urinary urgency, recurrent UTI, or menopause symptoms.
- The current manufacturer page says the same thing. Cynosure’s current MonaLisa Touch indication lists those broad soft-tissue uses and does not list GSM.
- ACOG addresses the symptom claim directly. Its current clinical consensus says laser therapy is neither FDA-approved nor FDA-cleared for treating menopause symptoms.
“FDA-cleared” and “FDA-approved” are not interchangeable marketing flourishes. A 510(k) clearance is a substantial-equivalence pathway for the device and its stated indications. It is not an FDA finding that the procedure treats GSM effectively.
Off-label use is not automatically illegal or improper. U.S. clinicians can use a legally marketed device off-label within professional practice. The patient-facing obligation is honesty: you should know that FDA did not clear or approve this device for the symptom result being sold to you.
What current clinic pages say
Three live price or treatment pages use FDA language that does not match the indication we found:
| Page | Live wording | What the current record supports |
|---|---|---|
| Duke Health | Calls it “FDA-approved technology” within a vaginal-dryness treatment description | The laser platform is cleared for broad soft-tissue uses; GSM is not named |
| Mercy Health | Calls it the first laser procedure of its kind “recognized by the FDA for treating GSM” | We found no GSM indication in K180193 or the current manufacturer indication |
| Dr. Thaïs Aliabadi | Calls it an “FDA-approved laser treatment for vaginal atrophy and laxity” | The platform is cleared; that treatment claim is not in the stated indication |
That does not prove intent. It proves the wording is too broad.
The one sentence to use at a consultation
“Please show me the FDA indication that names the condition you are proposing to treat.”
If the answer is “the device is cleared for gynecology,” you now know what that does—and does not—mean.
Does MonaLisa Touch actually work?
The evidence is divided, and study design explains much of the division. Before-and-after studies frequently report improvement. Sham-controlled trials are mixed: one small trial favored laser, while several others—including a larger 12-month trial and a breast-cancer-survivor trial—did not show a meaningful advantage over sham. Current U.S. guidance does not support routine use.
Here is the part sales pages usually collapse into one word: “studied.”
| Study | Design and population | What happened |
|---|---|---|
| Salvatore et al., 2021 | Double-blind sham-controlled trial; 58 eligible participants; three sessions; four-month follow-up | The active group had statistically significant improvements over sham on several symptom and sexual-function outcomes |
| Cruff and Khandwala, 2021 | Double-blind sham-controlled trial; 30 participants | Both groups improved; there was no between-group difference in the primary improvement result. The study was small and underpowered |
| Li et al., JAMA 2021 | Double-blind sham-controlled trial; 85 participants; three treatments; 12-month follow-up | No significant laser advantage for symptom severity, quality of life, vaginal health index, or histology |
| LIGHT trial, 2023 | Sham-controlled trial in breast-cancer survivors receiving aromatase inhibitors; 72 randomized; five monthly procedures; both groups also used a moisturizer and vaginal vibrator stimulation | No significant between-group differences in the primary or secondary outcomes at six months; both groups improved on some measures |
| Jaber et al., 2025 | Sham-controlled trial in 34 breast-cancer survivors; three sessions followed by an open-label extension offering up to six active treatments | No significant laser-versus-sham difference after the randomized three-session phase; additional treatments produced modest changes that remained below the stated threshold for clinical significance |
The draft originally credited the Cruff–Khandwala study as the sham trial that found a benefit. It did not. The favorable sham-controlled trial is Salvatore. That distinction matters because “one trial found benefit” is fair; assigning the finding to the wrong trial is not.
The newest synthesis is the August 2026 comparator-aware systematic review and meta-analysis. It included 36 studies, 1,709 participants, 11 randomized trials, and 407 cancer survivors. It found short-term improvement signals, but those signals became smaller when laser was compared with sham rather than baseline or a less rigorous comparator. The authors described the certainty as limited and the long-term durability question as unresolved.
The 2025 AUA/SUFU/AUGS guideline on GSM reaches the practical conclusion: evidence does not support routine use of CO2 laser, Er:YAG laser, or radiofrequency for GSM, and clinicians should explain the uncertainty.
There is published pushback. A 2020 review of the literature and FDA adverse-event database argued that the FDA’s risk warning may have overstated the apparent frequency of serious events. That is a legitimate safety argument. It is not proof of symptom efficacy, durability, or cost-effectiveness.
The honest one-sentence summary
Some women may improve, but the best-controlled evidence does not let a clinic predict that you will improve, how much, or how long it will last.
The line from the trial that belongs on a cost page
The 2021 JAMA trial cited a reported annual laser cost of $2,733 and concluded that, with no demonstrable difference from sham in that study, the treatment could not be considered cost-effective. The $2,733 input came from a 2020 decision model that had reached the opposite economic conclusion by assuming published efficacy and adherence; once the sham trial found no treatment difference, its authors rejected that premise. The JAMA conclusion is not a universal U.S. price ruling, but the conflict is exactly what a cost page should show.
Why there are no treatment testimonials here
A clinic-curated testimonial can tell you that one person was pleased. It cannot give you the response rate, the number who did not improve, the durability curve, or the denominator. We did not use testimonials to answer an efficacy question the controlled evidence has not closed.
What does vaginal estrogen actually cost?
At current recurring cash-discount prices, a 42.5 g tube costs $35.51 to $41.88. Using the label’s 2–4 g starting range, taper, then 1 g twice-weekly maintenance, five calendar years require about 13 to 15 whole tubes: $462 to $628. A maintenance-only five-year model is $462 to $544; clinician care and different dosing add cost.
This is the comparison that can make a four-figure laser package feel inevitable.
Mercy Health’s April 2026 page says vaginal estrogen can exceed $400 for a six-week tube. That can describe a particular brand price, pharmacy, benefit design, or higher-use phase. It does not describe the current transparent generic cash prices we found, and it does not describe the FDA label’s maintenance example.
| Input | What we verified September 1, 2026 | What it means |
|---|---|---|
| Tube size | The DailyMed label supplies 42.5 g | Tube life depends on grams used, not the word “monthly” |
| Loading and taper | The label describes 2–4 g daily for one or two weeks, then a reduced dose for a similar period | The first tube may disappear faster than a maintenance tube |
| Maintenance example | 1 g one to three times weekly after restoration of the vaginal mucosa | At 1 g twice weekly, modeled use is 104 g a year, or about 2.45 tubes; five years consumes 520 g, or about 12.24 tubes |
| SingleCare | $32.51 for one 42.5 g generic tube with a one-time $3 sign-up bonus; $35.51 without that bonus | Do not annualize a first-use bonus across five years |
| GoodRx | Location- and pharmacy-dependent coupon pricing | Use the live pharmacy quote for your ZIP code rather than a national-looking headline |
| Drugs.com | $41.88 for 42.5 g | Cash discount price; not an insurance copay and not guaranteed |
Using $35.51 to $41.88 as the recurring transparent range:
| Estradiol cream model | Five-year use | Whole tubes purchased | Current modeled outlay |
|---|---|---|---|
| Maintenance only: 1 g twice weekly for five years | About 520 g | 13 | $462–$544 |
| Label low-start example: 2 g daily for 1 week, then 1 g daily for 1 week, then maintenance | About 537 g | 13 | $462–$544 |
| Label high-start example: 4 g daily for 2 weeks, then 2 g daily for 2 weeks, then maintenance | About 596 g | 15 | $533–$628 |
The full label-based five-year envelope is therefore $462 to $628 in whole-tube purchase outlay. The minimum and maximum are not predictions; they show what the label’s starting range does to the checkout math before any clinician-prescribed variation.
The number changes if your clinician prescribes 1 g three times weekly, a larger dose, repeated loading, another formulation, or a brand product. Insurance can make the price lower—or force a different product. The point is not that every woman spends $87. The point is that “$400 every six weeks for life” is not a fair default description of generic cream at label maintenance dosing.
Two questions that expose a bad cost comparison
- Which exact product and package size are you pricing? “Vaginal estrogen” is not one price.
- Which dosing phase are you annualizing? A short loading schedule should not be silently multiplied across every year.
That is not haggling. That is asking the seller to use the same assumptions for both options. For formulations, use, label differences, and practical questions, see our vaginal estrogen guide.
If the lower-cost prescription route may fit, do not start with a provider ad. Start with your situation.
Use Find My HRT Path to see whether online care, an in-person exam, or your current clinician is the right first stop.
How does MonaLisa Touch compare with every other option on five-year cost?
The answer changes sharply by product and eligibility. Generic estradiol cream is far below the laser model; Intrarosa at the cash price is far above it, while the manufacturer’s $35 commercial-copay statement can change near-term cost without establishing a five-year price. Osphena’s official direct-program arithmetic is below the median laser model if terms persist. Costs do not establish equal outcomes.
| Option and modeled route | Current price input | Five-year modeled cash outlay | What the number excludes |
|---|---|---|---|
| MonaLisa Touch — 3-touch-up public-price model | Each clinic’s published initial and maintenance price | $3,300–$4,500; median $3,950 | Consultation, travel, complications, external add-ons, tax, financing |
| MonaLisa Touch — 4-touch-up public-price model | Each clinic’s published initial and maintenance price | $3,800–$5,100; median $4,550 | Same exclusions |
| Generic estradiol vaginal cream — medicine only | $35.51–$41.88 per 42.5 g; label starting range + 1 g twice-weekly maintenance | $462–$628 for 13–15 whole tubes | Visit, exam, clinician-prescribed variation, dispensing/shipping |
| Generic cream + Midi self-pay visit scenario | $250 initial + four $150 yearly follow-ups + 13–15 whole tubes | $1,312–$1,478 | Any extra visits, exam elsewhere, labs, different medication use |
| Intrarosa — current displayed GoodRx cash price | $233.16 per 28 inserts; one insert daily | About $15,197 | Price changes, visit, tax/shipping |
| Intrarosa — current commercial savings statement | Manufacturer site: eligible commercially insured patients may pay as little as $35 per 28 inserts | Five-year total not modeled because the public statement does not establish a five-year term | Enrollment approval, duration, maximum benefit, plan interaction, and future program changes |
| Osphena — current commercial direct program | As little as $90 per 90 tablets | About $1,825 if eligibility and terms stayed unchanged | Visit, future program or eligibility changes |
| Osphena — current uninsured or non-covered direct program | $190 per 90 tablets | About $3,853 if terms stayed unchanged | Visit and future program changes |
| Moisturizer and lubricant | Product price × actual frequency | Not modeled as one universal total | Products, package sizes, use, and needs vary too widely for an honest single number |
The medication facts matter as much as the prices:
- Generic estradiol vaginal cream is an FDA-approved estrogen prescription. It is not appropriate for every person, and the label carries estrogen warnings.
- Intrarosa is prasterone, also called DHEA. It is a steroid converted locally into estrogen and androgen metabolites. Calling it simply “non-hormonal” erases its pharmacology. Its FDA-approved indication is moderate to severe pain during sex due to menopause.
- Osphena is ospemifene, an oral estrogen agonist/antagonist. It is not estrogen, but it acts at estrogen receptors and carries boxed warnings and contraindications. It is approved for moderate to severe dyspareunia or vaginal dryness due to menopause.
- MonaLisa Touch is a procedure used off-label for GSM. Its device clearance and the evidence question were covered above.
The lane inversion, corrected
There is a cash-price lane where the laser is cheaper: a person paying the current displayed GoodRx cash-discount price for Intrarosa every 28 days would spend roughly three times the median four-touch-up laser model over five years.
That is not the whole market. The current official Intrarosa patient site says eligible commercially insured patients may pay as little as $35 per 28-day supply. That may cut near-term cost sharply, but the public statement does not create a verifiable five-year price. Osphena’s official direct program lists $90 per 90 tablets with commercial insurance or $190 per 90 tablets without coverage; holding those terms constant puts the five-year arithmetic below the $4,550 laser median.
A price comparison that ignores savings eligibility is incomplete. A medical comparison that treats these options as interchangeable is worse. The prescription labels, cancer history, clot history, unexplained bleeding, medication interactions, symptom location, and willingness to use a daily product can change which rows are even available to you.
What if vaginal estrogen is not an option for you?
“I cannot use vaginal estrogen” can mean several different things: a confirmed contraindication, a cancer-history decision that needs shared decision-making, a side effect, inadequate response, personal preference, or a broad “no hormones” instruction that was never revisited. Those situations should not be collapsed. Intrarosa and Osphena are prescription alternatives, but neither is accurately described as a simple non-hormonal escape hatch.
If you are a breast-cancer survivor, take an aromatase inhibitor, have unexplained bleeding, have a clot history, or were told to avoid hormones, this is not the section to turn into a self-serve shopping list.
Intrarosa: The current DailyMed label explains that prasterone is converted to active estrogens and androgens. Its labeling warns about current or past breast cancer because estrogen is a metabolite and the product has not been studied in women with that history.
Osphena: The current DailyMed label identifies ospemifene as an estrogen agonist/antagonist and carries boxed warnings involving the endometrium and cardiovascular disorders. It is not a neutral default for someone with a hormone-sensitive cancer or thromboembolic history.
Laser: The LIGHT trial studied breast-cancer survivors taking aromatase inhibitors. Both the laser and sham groups also received a nonhormonal first-line routine, and the laser did not separate from sham at six months. A second 2025 sham-controlled trial in 34 breast-cancer survivors likewise found no significant difference after three sessions; additional open-label sessions produced modest changes below the study’s clinical-significance threshold. That does not prove nobody responds. It means two directly relevant randomized trials did not establish an added benefit in that setting.
Low-dose vaginal estrogen after breast cancer: Major professional guidance does not reduce this to an automatic yes or no. The decision can depend on symptom severity, prior treatments, cancer type, current endocrine therapy, recurrence risk, and coordination with oncology. Use our evidence pages to prepare for that conversation—not to replace it:
The cheapest responsible first step is usually not a device quote. It is confirming which constraint is real and which options remain open. A sentence said years ago—“you can never use hormones”—may still be the right sentence. It may also need a more specific, current conversation.
We do not place a provider CTA in this section. A cancer-history or contraindication decision belongs with the clinicians who know that history.
Is MonaLisa Touch safe?
Short-term trial data did not show a large excess of severe events, but that is not the same as proving the procedure risk-free. The manufacturer lists specific contraindications and possible adverse effects, and the FDA has received reports involving burns, scarring, pain during sex, and chronic pain from energy-based vaginal procedures. The frequency and long-term risk remain uncertain.
The fairest safety answer has three layers.
What controlled trials reported
In the 2021 JAMA sham-controlled trial, 16 participants in the laser arm and 17 in the sham arm reported an adverse event, and none was severe. Reported problems included self-resolving vaginal pain or discomfort, spotting, urinary symptoms or infection, and discharge. The similarity matters: some short-term effects may come from the procedure, insertion, examination, or the underlying condition rather than the laser energy alone.
The LIGHT trial also did not identify a significant safety difference at six months. Neither trial was large enough to rule out uncommon harms or establish multi-year safety.
What the current manufacturer page says
Cynosure’s current MonaLisa Touch product page lists these contraindications:
- An undiagnosed lesion in the vagina, cervix, or target treatment area.
- Active vaginal or vulvar infection.
- Pregnancy or fewer than three months postpartum.
- Prolapse beyond the hymen.
- Prior vaginal or colorectal radiation.
- Prior reconstructive pelvic surgery using mesh kits.
- Impaired wound healing.
- A history of keloid formation.
- Anticoagulation treatment or a thromboembolic condition.
Its current possible-side-effects list includes spotting, mild vaginal bleeding, pink or brown discharge, mild to profuse watery discharge, redness, swelling, inflammation, tenderness, itching, irritation, burning with urination, pinpoint bleeding, and discomfort.
That is a manufacturer list, not a prediction that each event is common. It is also the reason “virtually no risk” is not an adequate consent conversation.
What the FDA warning and published pushback mean
In 2018, the FDA warned about energy-based devices marketed for vaginal “rejuvenation” and menopause-related symptoms after receiving reports that included burns, scarring, painful sex, and chronic pain. A 2020 review challenged how the warning grouped medical GSM treatment with cosmetic procedures and argued that the apparent risk had been overstated.
Both facts can be true: the warning may not establish a reliable event rate, and serious reported events still should not disappear from informed consent.
The radiation contradiction is not a footnote
People who developed symptoms after pelvic cancer treatment may be looking for a non-estrogen option. The current manufacturer page lists prior vaginal or colorectal radiation as a contraindication. Mercy’s April 2026 page, by contrast, says treatment often can be tailored safely after radiation when the history is disclosed. If that history applies to you, ask the clinic to reconcile those two statements in writing before treatment.
Follow the treating clinician’s aftercare plan. Promptly seek medical evaluation for persistent or worsening pain, substantial bleeding, fever, foul-smelling discharge, difficulty urinating, or another severe or new symptom.
What else can look like GSM before you spend $2,100?
Dryness, burning, itching, pain with penetration, urinary symptoms, and vulvar irritation are not specific to GSM. Lichen sclerosus, infection, contact dermatitis, focal vestibular pain, pelvic-floor dysfunction, vulvar lesions, and other conditions can overlap. Unexplained postmenopausal bleeding, a new lesion, white or thickened skin, tearing, focal pain, discharge, or odor belongs with an in-person exam before a laser package.
The worst outcome is not merely paying for a treatment that does not help. It is paying to treat the wrong problem.
| Pattern that should stop the checkout | Why an exam matters | What the laser quote cannot answer |
|---|---|---|
| White, pale, thickened, shiny, or easily torn vulvar skin | Can occur with lichen sclerosus or another vulvar dermatosis | Whether a skin-directed treatment and ongoing surveillance are needed |
| Pain concentrated at the vaginal entrance | May involve the vestibule, pelvic floor, skin, scar, or nerve sensitivity | Whether an internal-only treatment reaches the painful tissue |
| New discharge, odor, burning, or sudden symptom change | Infection and inflammation can overlap with GSM | Which organism or condition is present |
| Symptoms linked to soaps, wipes, liners, detergents, or topical products | Irritant or allergic contact dermatitis can mimic dryness and burning | Which exposure should be removed |
| Unexplained bleeding after menopause | Requires evaluation rather than symptom treatment alone | The source of bleeding |
| A new lump, ulcer, pigment change, or persistent lesion | Needs direct inspection and sometimes testing | Whether the tissue is safe to treat |
ACOG’s 2026 update on postmenopausal bleeding reinforces that bleeding after menopause needs evaluation rather than symptom treatment alone. A 2023 lichen sclerosus review describes the typical whitish atrophic patches, itching or soreness, scarring risk, and the role of examination and biopsy when the picture is unclear or a neoplasm is suspected.
Multiple pages in the price sample market MonaLisa Touch for lichen sclerosus, and at least one publishes a separate lichen-sclerosus price. A menu entry is not a diagnosis and should not displace standard management: the 2023 review calls long-term potent or ultrapotent topical corticosteroids the gold-standard therapy and recommends biopsy when the diagnosis is unclear, treatment fails, or a neoplasm is suspected. A laser quote that arrives before that workup is backwards.
A telehealth history can help decide the next step. It cannot inspect the vulva, locate pain precisely, perform a speculum exam, collect a swab, or biopsy a lesion. If the missing information is visual or tactile, another video call is not the answer.
If you need an exam, book an exam—not a laser sales consultation.
Sesame lists in-person women’s-health visits in some markets with prices shown before booking and does not bill insurance. Confirm that the specific clinician will perform the pelvic or vulvar exam you need before paying. Availability and price depend on location. See our affiliate disclosure.
Why do so many MonaLisa Touch clinics make you call for the price?
Many clinic pages describe the procedure but omit the price. The public record offers economic context, not proof of any individual clinic’s motive: a 2018 federal complaint alleged an equipment price above $150,000 and aggregate lease payments above $200,000. At a $2,100 initial package, that equals roughly 72 to 96 patient courses before staff, space, supplies, financing, service, and profit.
A federal complaint in Three R LLC et al. v. Cynosure, Inc., No. 3:18-cv-30133-MGM in the District of Massachusetts, alleged that a MonaLisa Touch system cost $150,000 or more and that aggregate lease payments exceeded $200,000. Those figures are allegations filed in 2018, not a current audited device price, a judicial finding, or evidence that any clinic in this price sample acted improperly.
The arithmetic is still useful:
- $150,000 ÷ $2,100 = about 72 gross initial courses.
- $200,000 ÷ $2,100 = about 96 gross initial courses.
That is before clinician and staff time, rent, training, maintenance, consumables, marketing, payment processing, financing, taxes, complications, or margin. It does not prove why a specific clinic uses packages or hides a price. It shows why a fixed-cost procedure can create financial incentives for package sales, repeat treatment, and less transparent local pricing.
The original price dataset adds the part the complaint cannot: publicly listed three-session prices vary 67% from $1,800 to $3,000. A market with the same branded procedure and wide local pricing is exactly where written comparison works.
Ask two questions that force the package back into units:
- What is the price for one session?
- What happens to the unused balance if I stop after session one or two?
A clinic that believes in the package should be able to explain both without making you feel difficult.
What should you ask before paying for MonaLisa Touch?
Ask for numbers, documents, and yes-or-no answers—not reassurance. The ten questions below expose the real total, the off-label status, whether the painful tissue is included, what happens if you stop, and whether another diagnosis has been ruled out. Send them before the consultation or carry them into the room.
- What is the all-in price in writing—including the consultation, every initial session, internal and external treatment, follow-up, and the first maintenance visit?
- How many sessions are included, and what is the price for one session instead of the package?
- Is my treatment internal only, external only, or both—and where do you believe my symptoms are coming from?
- What is the maintenance interval, what does one maintenance visit cost today, and can that price change after I buy the initial package?
- What happens financially if I stop after one or two sessions? Is any portion refundable or transferable?
- What happens if I have no meaningful improvement? Does another session cost more, and what endpoint are we using to decide?
- Please show me the FDA indication that names the condition you plan to treat. Am I being treated off-label?
- Have I had the exam needed to rule out infection, lichen sclerosus, a lesion, focal vestibular pain, pelvic-floor dysfunction, or another cause?
- Do any of the manufacturer’s contraindications apply to me, including prior radiation, mesh surgery, anticoagulation, impaired healing, or a thromboembolic condition?
- Which lower-cost, guideline-supported options have I tried, for how long, and why are they not appropriate now?
Print this section or save it as a PDF before the appointment. No email, symptom form, or purchase is required. The micro-commitment is not “book the laser.” It is “get the written answers.”
How do you get the lower-cost prescription option?
The generic cream is inexpensive; access to a prescriber and the right exam are the actual bottlenecks. Your existing gynecologist or primary-care clinician is the cleanest first route. Midi is a virtual option with $250 self-pay initial visits and $150 follow-ups, while Sesame offers pay-per-visit care and some in-person women’s-health listings. Neither route guarantees a prescription.
Route 1: ask the clinician you already have
Say the exact thing you want to discuss: “Could we talk about local vaginal estrogen and whether I need an exam first?”
This route can use your existing records, may be covered by your plan, and can combine the prescription conversation with the in-person examination that a screen cannot perform. We earn nothing when you use it. It is still the first route we would try.
Route 2: use insurance-oriented menopause telehealth when an exam is not the missing step
Midi’s current pricing and insurance page lists a $250 self-pay initial visit and $150 continued-care visits, with no membership fee. Midi says care is available in all 50 states; network participation, deductible, copay, coinsurance, authorization, and medication benefits still depend on the plan. Prescriptions, when clinically appropriate, are sent to a pharmacy rather than bundled into the visit price.
What we would rather tell you before the CTA
Midi cannot inspect a vulvar lesion, collect a swab, perform a pelvic-floor examination, or locate entrance pain through a screen. If the unanswered question requires an exam, Midi is not the right first step. Use an in-person clinician.
The Medicare and Medicaid limits are also asymmetric:
- Medicare: Midi is out of network. Medicare beneficiaries may use Midi as self-pay patients, but Midi says claims related to its visits, medications, or associated services cannot be submitted to Medicare.
- Medicaid or Medi-Cal: Midi says it cannot accept these beneficiaries at this time, including as self-pay patients.
That is a real exclusion. It does not get softened because The HRT Index may earn a commission from eligible Midi referrals.
Why Midi remains a fit for some readers: it does not make the four-figure procedure the product. For someone who has already had the necessary exam and wants a virtual menopause clinician to assess an FDA-approved prescription, the model can separate the clinical visit from the pharmacy price. That is the practical strength.
Does that match your situation?
Check Midi’s current insurance and self-pay terms before booking. A prescription is not guaranteed, and an in-person exam may still be required.
Route 3: pay per visit or find a listed in-person appointment
Sesame’s FAQ says it does not bill health insurance. It lists prices before booking, and its women’s-health marketplace includes virtual and, in some locations, in-person appointment types. The provider, service, availability, and price change by market.
That model can fit someone who wants a single cash visit instead of an ongoing program. It is not automatically an exam: read the appointment description and confirm the clinician will perform the specific pelvic or vulvar evaluation you need.
Prefer a visible cash price or need to search for an in-person women’s-health visit?
Check current Sesame appointment types and prices in your location.
Affiliate disclosure: The HRT Index may earn a commission from eligible provider links. That does not change the route order above: your current clinician first, an in-person exam when the missing answer requires one, then virtual or marketplace care when it fits. Read the affiliate disclosure.
How did The HRT Index price and check this page?
Every headline number traces to a named public source and a visible calculation. Clinic prices were recorded as provider-stated figures, not phone-confirmed quotes. Regulatory and medical claims were checked against FDA records, current manufacturer material, professional guidance, prescribing information, and peer-reviewed studies. Commercial prices remain time-sensitive.
This page follows The HRT Index Verification Standard. For provider research, the framework checks five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access. It is a documented process, not a numeric score, and no treatment or provider receives an invented rating here.
Price dataset method
- We searched for U.S. clinic and health-system pages displaying a public MonaLisa Touch price.
- We included eight pages that stated a usable initial-course number.
- We recorded the visible session count, maintenance price and interval, and page date when available.
- We calculated median and arithmetic mean from the eight initial prices.
- We calculated the maintenance median and mean from the six pages with a published maintenance number.
- We modeled three and four paid touch-ups because “every 12–18 months” does not map honestly to one universal five-year count.
- We did not call the clinics, imply appointment availability, or treat an undated page as a guaranteed current quote.
Medication method
- Generic estradiol was modeled with the label’s low and high starting examples—2–4 g daily for one or two weeks, then half the initial daily dose for a similar period—followed by 1 g twice-weekly maintenance within the label’s one-to-three-times-weekly range.
- A 42.5 g tube supplies about 20.4 weeks at the modeled maintenance frequency. Five maintenance-only years consume about 520 g and require 13 whole tubes; adding the label’s starting range produces about 538 to 597 g over five calendar years and requires 13 to 15 whole tubes.
- Intrarosa was modeled at one insert daily and 365 ÷ 28 packages per year.
- Osphena was modeled at one tablet daily and 365 ÷ 90 packages per year.
- The Intrarosa $35 manufacturer statement was not projected across five years. Osphena’s official direct-program prices were held constant only to show current-program arithmetic; they are not five-year guarantees.
- We kept medication price, clinician price, and procedure price separate until a clearly labeled scenario combined them.
Evidence method
We prioritized sham-controlled trials because they test whether laser energy adds benefit beyond attention, examination, insertion, expectation, and co-interventions. We included the favorable sham trial and the unfavorable or neutral trials rather than selecting one direction. We then placed those trials against the latest systematic review and current U.S. guidance.
What can go stale
| Element | Refresh cadence | Verification method |
|---|---|---|
| Public clinic and maintenance prices | Quarterly and immediately before a major update | Open each clinic page; record visible date and package wording; phone verification only if labeled as such |
| Drug cash prices and savings programs | Monthly | Open the live price page and official program terms; do not carry a one-time bonus into recurring math |
| Insurer policies | Quarterly | Check policy effective date, review date, status, code section, and product applicability |
| FDA indication and manufacturer contraindications | Quarterly, and immediately after a device-label or safety update | Check FDA 510(k)/safety records and current manufacturer page |
| Clinical evidence and guidance | Quarterly | Search PubMed and professional-society guideline pages for new sham trials, systematic reviews, and updates |
| Midi and Sesame terms | Monthly | Check current official pricing, insurance, eligibility, and service pages |
What this page does not claim
It does not claim that eight clinics equal the national market, that any price will still be live at checkout, that five-year touch-up use is medically necessary, that all insurers deny every claim, that a coupon will remain available, or that any treatment is right for you. The calculations are reproducible. The medical decision is individual.
This is editorial research, not medical advice, and it has not been medically reviewed by a clinician. For the site-wide process, see The HRT Index methodology.
What are the most common MonaLisa Touch cost questions?
The questions below close the price, coverage, FDA-status, safety, durability, and alternative-treatment follow-ups most likely to send someone searching again. Each answer uses the same September 2026 price data and source hierarchy as the full article. A personal treatment decision still requires the clinician who knows your history and can examine you when needed.
How much does one MonaLisa Touch session cost?
In this eight-clinic sample, the implied or published per-session amount is about $450 to $1,000. Some figures come from dividing a package price, so ask whether a single session can actually be purchased at that amount.
How much is MonaLisa Touch for three treatments?
The exact three-session public prices we found were $1,800 to $3,000. The eight-clinic initial-course median was $2,100, but Duke’s $1,800 package includes three to four sessions and Horizons caps the initial series at $1,800 even if more than three are needed.
How much does MonaLisa Touch cost over five years?
Using the six clinics with public maintenance prices, a three-touch-up model totals $3,300 to $4,500 with a $3,950 median. A four-touch-up model totals $3,800 to $5,100 with a $4,550 median. Consultation, travel, add-ons, financing, and complications are excluded.
Does insurance cover MonaLisa Touch?
Expect self-pay. The current Aetna, Capital Blue Cross, Arkansas Blue Cross and Healthy Blue North Carolina policies we checked treat MonaLisa Touch or the relevant vaginal-laser use as investigational, not medically necessary, cosmetic, or non-covered. Your specific contract and date of service still control.
Is MonaLisa Touch covered by Medicare?
CMS has a general national coverage determination for laser procedures, but it does not affirmatively cover MonaLisa Touch for GSM. In the absence of a specific national instruction, a Medicare Administrative Contractor may determine whether a laser procedure is reasonable and necessary. Ask the clinic and contractor for the code-specific answer in writing.
Can you use an HSA or FSA for MonaLisa Touch?
Possibly. Eligibility depends on the medical purpose and the plan’s substantiation rules, not the clinic’s promise. Ask the administrator before paying and request the required diagnosis, itemized receipt, and letter-of-medical-necessity rules in writing.
Is MonaLisa Touch FDA approved?
No—not for GSM or menopause symptoms. The SmartXide Touch platform is FDA-cleared for broad soft-tissue surgical uses, including gynecology and genitourinary surgery. GSM, vaginal dryness, painful sex, and menopause symptoms are not named in the current indication; this use is off-label.
Does MonaLisa Touch really work?
The controlled evidence is mixed. One small sham-controlled trial favored laser, while several others—including a larger 12-month trial and the LIGHT breast-cancer-survivor trial—did not establish an added benefit over sham. The 2025 AUA/SUFU/AUGS guideline does not support routine use, and the 2026 meta-analysis describes limited certainty and unresolved durability.
How many treatments will you need?
Three initial sessions are common on the public clinic pages, generally spaced weeks apart. Duke publishes three to four, and Horizons says some patients may need more without exceeding its initial $1,800 cap. Your quote should state the included number and the price of any extra session.
How long do MonaLisa Touch results last?
Clinic pages commonly recommend maintenance every 12 to 18 months, but that commercial schedule is not proof that a specific benefit lasts that long. Sham-controlled evidence has not established a predictable response or durability curve for an individual patient.
What are the contraindications for MonaLisa Touch?
The current manufacturer list includes undiagnosed lesions, active vaginal or vulvar infection, pregnancy or fewer than three months postpartum, prolapse beyond the hymen, prior vaginal or colorectal radiation, prior mesh-kit pelvic reconstruction, impaired healing, keloid history, anticoagulation treatment, and thromboembolic conditions.
What are the side effects of MonaLisa Touch?
The current manufacturer page lists spotting or mild bleeding, pink, brown, or watery discharge, redness, swelling, inflammation, tenderness, itching, irritation, burning with urination, pinpoint bleeding, and discomfort. The FDA warning described reports including burns, scarring, painful sex, and chronic pain. Trial events were mostly non-severe, but uncommon and long-term risks remain uncertain.
What is the cheapest prescription alternative to MonaLisa Touch?
Among the specific prescription prices modeled here, generic estradiol vaginal cream is the least expensive for someone who can appropriately use it: about $462 to $628 in whole-tube purchase outlay over five calendar years using the label’s starting range and 1 g twice-weekly maintenance. Clinician care and a different prescribed dose can change the total.
Are Intrarosa and Osphena non-hormonal?
That label is too simple. Intrarosa is the steroid prasterone, which is converted into estrogen and androgen metabolites. Osphena is an estrogen agonist/antagonist that acts at estrogen receptors. Neither is the same as vaginal estrogen, but neither should be presented as biologically hormone-free.
Is MonaLisa Touch worth the cost?
It may be a deliberate choice for someone who has had the right exam, understands the off-label status and uncertain evidence, cannot or will not use suitable alternatives, and accepts the cash risk. It is hard to justify as a first purchase when a cheaper guideline-supported option remains appropriate and untried.
Can you get MonaLisa Touch after breast cancer?
Clinics market it to breast-cancer survivors, but candidacy is individual and the manufacturer contraindication list includes prior vaginal or colorectal radiation. The LIGHT trial and a 2025 sham-controlled trial in breast-cancer survivors did not establish an added benefit after the randomized phases. Coordinate the decision with oncology and the clinician treating the symptoms.
What happens if MonaLisa Touch does not work?
There is no standard refund or retreatment rule across the public pages. Before prepaying, get the stop-after-one-or-two-session terms, the definition of meaningful improvement, the price of any extra treatment, and the complication follow-up plan in writing.
What should you do next?
Start with the unresolved decision, not the most persuasive checkout page. An unevaluated symptom needs an exam; an appropriate lower-cost prescription deserves a fair trial discussion; a cancer-history or contraindication question needs the clinicians who know that history. Choose a laser only after those paths have been made visible.
If your symptoms have never been examined: stop price-shopping and arrange the exam.
If you can appropriately use vaginal estrogen: ask your existing clinician about the generic first. It is the lowest-cost prescription route in this comparison, and telling you that earns us nothing. If you are still sorting local therapy from systemic treatment, start with the types of HRT.
If you need virtual menopause care and an exam is not the missing step: check whether Midi’s current insurance or self-pay model fits—but read the Medicare, Medicaid and exam limitations first.
If you need a visible cash price or a local in-person listing: check the exact Sesame appointment type before booking; do not assume a video visit includes an exam.
If vaginal estrogen is not straightforward because of breast cancer, aromatase-inhibitor use, bleeding, clot history, or another risk: take the labels and the evidence to the clinicians who know that history.
If you still choose the laser: that is your decision. Get the all-in five-year number, the contraindication review, the off-label answer, the tissue being treated, and the refund terms in writing. Go in knowing exactly what you are buying.
Still not sure which HRT program is right for you?
Use Find My HRT Path to get a situation-matched next-step plan.
It asks about symptoms, age, uterus status, medication-route preference, risk history, insurance or cash-pay situation, and state. It also flags when online care is not the right starting point.
Which sources support this page?
The source list separates regulatory records, clinical evidence, payer policies, direct clinic prices, medication labels, savings programs, and economic context. Prices and policies were retrieved or reviewed for the September 2026 update; older clinical and regulatory documents remain listed when they still govern the claim.
Regulatory, safety, and clinical guidance
- U.S. Food and Drug Administration, 510(k) K180193 — SmartXide family.
- FDA 510(k) Summary K180193.
- Cynosure, MonaLisa Touch product page — indication, contraindications, and possible side effects, retrieved September 1, 2026.
- American College of Obstetricians and Gynecologists, Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer.
- ACOG, Elective Female Genital Cosmetic Surgery — summary of the FDA’s 2018 energy-device warning.
- ACOG, Updated Guidance on Evaluating Postmenopausal Bleeding, April 16, 2026.
- De Luca DA, et al. Lichen sclerosus: The 2023 update. Frontiers in Medicine. 2023.
- AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, 2025.
- IRS Publication 502, Medical and Dental Expenses.
Controlled trials and evidence syntheses
- Li FG, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms. JAMA. 2021.
- Mension E, et al. The LIGHT Randomized Clinical Trial. JAMA Network Open. 2023.
- Jaber S, et al. CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers. 2025.
- Cruff J, Khandwala S. Double-Blind Randomized Sham-Controlled Trial. Journal of Sexual Medicine. 2021.
- Salvatore S, et al. Randomized Sham-Controlled Trial. Climacteric. 2021.
- Fractional CO2 Laser for Genitourinary Syndrome of Menopause: Comparator-Aware Systematic Review and Meta-Analysis. International Urogynecology Journal. 2026.
- Guo JZ, et al. Vaginal laser treatment of GSM: does the evidence support the FDA safety communication?. 2020.
- Wallace SL, et al. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies. American Journal of Obstetrics and Gynecology. 2020.
Payer policies
- Aetna CPB 0427 — Carbon Dioxide Laser, last review July 8, 2026.
- Capital Blue Cross MP 4.047 — Laser Treatment of Vulvovaginal Atrophy and Vaginal Rejuvenation, effective March 1, 2026.
- Arkansas Blue Cross and Blue Shield Coverage Policy 2018019, effective June 1, 2026; last review July 2026.
- Healthy Blue North Carolina ANC.00009, last review May 14, 2026; published July 1, 2026.
- CMS National Coverage Determination 140.5 — Laser Procedures.
Public clinic prices
- Duke Health — MonaLisa Touch Laser Treatment for Vaginal Dryness, updated July 19, 2023.
- Women’s Health Associates — MonaLisa Touch, retrieved September 1, 2026.
- Horizons Health & Wellness — MonaLisa Touch, retrieved September 1, 2026.
- Mercy Health — MonaLisa Touch Menopause Treatment, published April 14, 2026.
- Idaho Urologic Institute — MonaLisa Touch, retrieved September 1, 2026.
- Rush University Medical Center — Vaginal Laser Treatment, retrieved September 1, 2026.
- Associates in Women’s Health Care — MonaLisa Touch Treatments, retrieved September 1, 2026.
- Dr. Thaïs Aliabadi — MonaLisa Touch, retrieved September 1, 2026.
Medication labels, prices, and programs
- DailyMed — Estradiol Vaginal Cream USP, 0.01%.
- SingleCare — Estrace/Generic Estradiol Prices, prices updated August 31, 2026.
- GoodRx — Estrace/Generic Estradiol Prices, retrieved September 1, 2026.
- Drugs.com — Estradiol Topical Price Guide, retrieved September 1, 2026.
- GoodRx — Intrarosa Prices, retrieved September 1, 2026.
- Intrarosa — Official Patient Site and Commercial Savings Statement, retrieved September 1, 2026.
- Drugs.com — Intrarosa Price Guide and Patient Assistance Listing, retrieved September 1, 2026.
- DailyMed — Intrarosa Prescribing Information, updated July 17, 2026; labeling revised January 2026.
- Osphena — Savings Programs, retrieved September 1, 2026.
- DailyMed — Osphena Prescribing Information.
- Midi — Pricing and Insurance, retrieved September 1, 2026.
- Sesame — Frequently Asked Questions, retrieved September 1, 2026.
- Sesame — Women’s Health, retrieved September 1, 2026.
Economic context
- Three R LLC et al. v. Cynosure, Inc., No. 3:18-cv-30133-MGM (D. Mass.), filed complaint. The equipment figures are identified as allegations, not findings or a current quote.
The HRT Index is an independent editorial resource. This page is educational research, not medical advice, and has not been medically reviewed by a clinician. FDA-approved medications and off-label device uses are identified separately. No compounded medication is presented as equivalent to an FDA-approved product.